HCM
ONCE

Highbridge Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Highbridge Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-60,000
Closed -$3.58M – 1898
2017
Q2 		$3.58M Buy
60,000
+55,746
+1,310% +$3.12M 0.05% 347
2017
Q1 		$227K Buy
+4,254
New +$253K ﹤0.01% 1281

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Highbridge Capital Management's ONCE Position: Q3 2017 in Review

Highbridge Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2017, closing a stake of 60,000 shares — an estimated $3.58M sold.

Highbridge Capital Management first reported a position in ONCE in Q1 2017 and held it in 2 quarters. The position peaked at $3.58M in Q2 2017. 163 funds tracked by Wall St. Rank hold ONCE as of Q3 2017.

  • Highbridge Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 60,000 Spark Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $3.58M.
  • Highbridge Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Highbridge Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $3.58M in Q2 2017.
  • 163 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.